Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
    • Transcripts
    • AGM Invitations
    • IPOs
  • inderesTV
  • Portfolio
  • Forum
  • Discovery
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Log in to your Inderes Free account to see all free content on this page.
Create account

NextCell Pharma

1.28 SEK

-5.74 %

Less than 1K followers

NXTCL

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data

Quarter data

Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for NextCell Pharma

Q4/242024Q1/25Q2/25Q3/25Q4/252025Q1/26
Revenue1.610.72.83.32.32.610.91.8
EBITDA-13.0-42.2-7.6-7.8-9.7-8.2-33.4-13.3
EBIT-13.6-43.2-8.3-8.5-10.4-8.8-35.9-13.9
EBIT-%-829.9 %-405.0 %-292.6 %-260.3 %-458.0 %-338.2 %-328.0 %-785.4 %
Profit before taxes-13.3-42.0-8.0-8.2-10.3-8.6-35.1-13.8
Net income-13.3-42.0-8.0-8.2-10.3-8.6-35.1-13.8
Login required

This content is only available for logged in users

Create account
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.